New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with advanced solid tumors.

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment ...

Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient ...

Without head-to-head trials, doctors balance MAIC efficacy data with factors like cost and safety to choose the best ARPI for each patient.

A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.

With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment ...

New data reveals sugemalimab significantly enhances survival rates in metastatic non–small cell lung cancer, establishing it as a key first-line treatment option.

An expert discusses the advances in managing CAR T-cell therapy toxicities, emphasizing aggressive early treatment of acute complications, the importance of coordinated long-term monitoring with ...